La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Ardelyx Croissance future
Future contrôle des critères 6/6
Ardelyx devrait augmenter ses bénéfices et son chiffre d'affaires de 65.5% et de 27.4% par an respectivement. Le BPA devrait croître de de 65.5% par an. Le rendement des capitaux propres devrait être 49.2% dans 3 ans.
Informations clés
65.5%
Taux de croissance des bénéfices
65.5%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.2% |
Taux de croissance des recettes | 27.4% |
Rendement futur des capitaux propres | 49.2% |
Couverture par les analystes | Good |
Dernière mise à jour | 05 Aug 2024 |
Mises à jour récentes de la croissance future
Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Recent updates
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 07Ardelyx Faces Rising Challenges Despite Revenue Growth
Aug 05Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Jul 13Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
Jul 05Ardelyx: Strong Execution, Fairly Valued
May 10Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)
May 03Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 03Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
Jul 31Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now
Apr 17Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Mar 30Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Dec 14What To Expect For Ardelyx In The Coming Month
Oct 18Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position
Oct 04Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale
Jun 30Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 546 | 116 | 167 | 163 | 8 |
12/31/2025 | 393 | -41 | -15 | 45 | 10 |
12/31/2024 | 304 | -62 | N/A | 8 | 10 |
6/30/2024 | 210 | -65 | -86 | -85 | N/A |
3/31/2024 | 159 | -66 | -81 | -81 | N/A |
12/31/2023 | 124 | -66 | -90 | -90 | N/A |
9/30/2023 | 134 | -27 | -67 | -67 | N/A |
6/30/2023 | 83 | -56 | -71 | -71 | N/A |
3/31/2023 | 63 | -66 | -87 | -87 | N/A |
12/31/2022 | 52 | -67 | -70 | -70 | N/A |
9/30/2022 | 9 | -114 | -124 | -124 | N/A |
6/30/2022 | 5 | -135 | -133 | -133 | N/A |
3/31/2022 | 4 | -153 | -137 | -136 | N/A |
12/31/2021 | 10 | -158 | -154 | -153 | N/A |
9/30/2021 | 11 | -151 | -133 | -131 | N/A |
6/30/2021 | 12 | -125 | -118 | -116 | N/A |
3/31/2021 | 13 | -105 | -102 | -101 | N/A |
12/31/2020 | 8 | -94 | -82 | -81 | N/A |
9/30/2020 | 8 | -85 | -75 | -75 | N/A |
6/30/2020 | 8 | -91 | -76 | -76 | N/A |
3/31/2020 | 6 | -91 | -85 | -85 | N/A |
12/31/2019 | 5 | -95 | -77 | -76 | N/A |
9/30/2019 | 3 | -103 | -84 | -84 | N/A |
6/30/2019 | 0 | -104 | -91 | -90 | N/A |
3/31/2019 | 0 | -100 | -81 | -80 | N/A |
12/31/2018 | 3 | -91 | -71 | -70 | N/A |
9/30/2018 | 45 | -53 | -47 | -47 | N/A |
6/30/2018 | 44 | -50 | -40 | -39 | N/A |
3/31/2018 | 44 | -53 | N/A | -45 | N/A |
12/31/2017 | 42 | -64 | N/A | -65 | N/A |
9/30/2017 | N/A | -106 | N/A | -97 | N/A |
6/30/2017 | N/A | -114 | N/A | -102 | N/A |
3/31/2017 | N/A | -117 | N/A | -103 | N/A |
12/31/2016 | N/A | -112 | N/A | -93 | N/A |
9/30/2016 | N/A | -98 | N/A | -87 | N/A |
6/30/2016 | N/A | -87 | N/A | -75 | N/A |
3/31/2016 | 18 | -50 | N/A | -80 | N/A |
12/31/2015 | 24 | -30 | N/A | -72 | N/A |
9/30/2015 | 30 | -16 | N/A | -54 | N/A |
6/30/2015 | 38 | 2 | N/A | -48 | N/A |
3/31/2015 | 29 | -6 | N/A | 6 | N/A |
12/31/2014 | 32 | -3 | N/A | 13 | N/A |
9/30/2014 | 34 | -4 | N/A | 28 | N/A |
6/30/2014 | 33 | -5 | N/A | 34 | N/A |
3/31/2014 | 31 | -7 | N/A | 5 | N/A |
12/31/2013 | 29 | -7 | N/A | 2 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ARDX devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.5% ).
Bénéfices vs marché: ARDX devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: ARDX devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ARDX ( 27.4% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ARDX ( 27.4% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ARDX devrait être très élevé dans 3 ans ( 49.2 %).